Literature DB >> 11598429

Fluoxetine and fluvoxamine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study.

V Ricca1, E Mannucci, B Mezzani, S Moretti, M Di Bernardo, M Bertelli, C M Rotella, C Faravelli.   

Abstract

BACKGROUND: : The treatment of binge eating disorder (BED) is still the object of debate. In the present study, the effectiveness of antidepressant drugs (fluoxetine - FLX - 60 mg/day, fluvoxamine - FLV -300 mg/day), cognitive-behavioural therapy (CBT) and combined treatments (CBT + FLX, CBT + FLV) has been evaluated in a randomized, clinical trial. Results at the end of the active treatment (in the 24th week) and 1-year follow-up outcomes have been evaluated.
METHODS: One hundred eight (44 M, 64 F) BED patients were randomly assigned to either CBT, FLX (60 mg/day), FLV (300 mg/day), CBT + FLX or CBT + FLV, for 24 weeks. At the beginning (T0), at the end (T1) of treatment and after 1 year (T2), body mass index (BMI) and eating attitude and behaviours (by EDE 12.0D) were assessed.
RESULTS: At T1, BMI and EDE scores were significantly reduced in CBT, CBT + FLX and CBT + FLV, but not in the FLX and FLV treatment groups. In the CBT + FLV group, a greater (p < 0.05) reduction of EDE total scores was observed, when compared to CBT + FLX or CBT treatment groups. At T2, BMI was significantly higher than at T1, but still significantly lower than at T0 in the CBT, CBT + FLX and CBT + FLV groups, while EDE scores remained unchanged from T1 in all treatment groups.
CONCLUSIONS: CBT was more effective than FLX or FLV in the treatment of BED. The addition of FLX to CBT does not seem to provide any clear advantage, while the addition of FLV could enhance the effects of CBT on eating behaviours. Modifications of eating behaviours are maintained at the 1-year follow-up, although the lost weight was partly regained. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598429     DOI: 10.1159/000056270

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN: 0033-3190            Impact factor:   17.659


  25 in total

1.  Predictors and moderators of response to cognitive behavioral therapy and medication for the treatment of binge eating disorder.

Authors:  Carlos M Grilo; Robin M Masheb; Ross D Crosby
Journal:  J Consult Clin Psychol       Date:  2012-01-30

2.  Treatment of binge eating disorder in racially and ethnically diverse obese patients in primary care: randomized placebo-controlled clinical trial of self-help and medication.

Authors:  Carlos M Grilo; Robin M Masheb; Marney A White; Ralitza Gueorguieva; Rachel D Barnes; B Timothy Walsh; Katherine C McKenzie; Inginia Genao; Rina Garcia
Journal:  Behav Res Ther       Date:  2014-05-02

Review 3.  Biological therapies for eating disorders.

Authors:  James E Mitchell; James Roerig; Kristine Steffen
Journal:  Int J Eat Disord       Date:  2013-07       Impact factor: 4.861

4.  Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.

Authors:  Marney A White; Carlos M Grilo
Journal:  J Clin Psychiatry       Date:  2013-04       Impact factor: 4.384

Review 5.  Pharmacological treatment of binge eating disorder: update review and synthesis.

Authors:  Deborah L Reas; Carlos M Grilo
Journal:  Expert Opin Pharmacother       Date:  2015-06-04       Impact factor: 3.889

6.  Clinical case discussion: binge eating disorder, obesity and tobacco smoking.

Authors:  Marney A White; Carlos M Grilo; Stephanie S O'Malley; Marc N Potenza
Journal:  J Addict Med       Date:  2010-03       Impact factor: 3.702

Review 7.  Current and emerging drug treatments for binge eating disorder.

Authors:  Deborah L Reas; Carlos M Grilo
Journal:  Expert Opin Emerg Drugs       Date:  2014-01-25       Impact factor: 4.191

Review 8.  Combining Pharmacological and Psychological Treatments for Binge Eating Disorder: Current Status, Limitations, and Future Directions.

Authors:  Carlos M Grilo; Deborah L Reas; James E Mitchell
Journal:  Curr Psychiatry Rep       Date:  2016-06       Impact factor: 5.285

9.  Review and meta-analysis of pharmacotherapy for binge-eating disorder.

Authors:  Deborah L Reas; Carlos M Grilo
Journal:  Obesity (Silver Spring)       Date:  2008-09       Impact factor: 5.002

10.  Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as.

Authors:  Carlos M Grilo; Marney A White
Journal:  Behav Res Ther       Date:  2013-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.